Calculus invests £2m in Oxford BioTherapeutics

London, 3 August 2018: Calculus Capital has invested £2m in Oxford BioTherapeutics (OBT), a clinical-stage oncology company that is developing next-generation cancer treatments. OBT has a strong pipeline of ‘immune-oncology’ (IO) therapies that are intended to provide more targeted, specialised … Continued